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Purpose: Recently, very late antigen-4 (VLA-4) has been shown to mediate initial mono- 
cyte adhesion and migration to the injured artery. We hypothesized that blocking 
monocyte adhesion using a specific monodonal antibody against VLA-4 may reduce 
intimal hyperplasia. 
Methods: Bilateral carotid endarterectomies were performed in eight adult baboons. 
Among them, five animals received an intravenous bolus injection of anti-VLA 4 anti- 
body (3 mg/kg) during surgery and again after 2 weeks. Three animals underwent 
bilateral carotid endarterectomies and served as untreated control subjects. Specimens 
were harvested at 4 weeks and subjected to morphometric analysis, cell proliferation 
assay, and immunostaining for macrophages. 
Results: All of the endarterectomized arteries were patent except for one in the treated 
group. The number of macrophages in the intimal tissues was significantly reduced in the 
treated arteries compared with that in the control vessels (15.78 --- 3.05 cells/section 
versus 33.50 - 6.13 cells/section; p < 0.001). The cell proliferation rate was significantly 
lower (p < 0.001) in the treated vessels (2.88% -+ 1.07%) compared with the control 
vessels (4.89% - 0.77%). The intimal area at the endarterectomized sites of carotid 
arteries was significantly less (p < 0.05) in the group treated with the anti-VLA-4 
antibody (1.10 -+ 0.68 rnm 2) than in the control group (2.00 + 0.52 ram2). 
Conclusion: These data show that blocking monocyte adhesion by use of an anti-VLA-4 
antibody significantly reduces the number of intimal macrophages, intimal cell prolifer- 
ation, and intimal hyperplasia n injured carotid arteries in baboons. This study supports 
a central role for macrophages in the development ofintimal hyperplasia and may suggest 
a new therapeutic strategy to prevent clinical restenosis. (J Vasc Surg 1997;26:87-93.) 
Intimal hyperplasia is one of the most frequent 
causes of late failure of every known vascular econ- 
structive procedure, including balloon angioplasty, 
atherectomy, surgical endarterectomy, and the inser- 
tion of vascular grafts. For example, endarterectomy, 
most often performed for carotid artery disease, in- 
volves surgical removal of the intimal layer and vary- 
ing amounts of the media. Development of intimal 
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hyperplasia has been well documented in patients 
who undergo carotid endarterectomy, and restenosis 
develops in 10% to 30% of patients during the first 
year.l-3 
Histologically, intimal hyperplasia is an accumu- 
lation of smooth muscle cells (SMCs) and matrix 
within the subendothelial portion of a vessel wall. An 
initial arterial injury stimulates proliferation of SMCs 
within the media. This is followed by migration of 
these cells across the internal elastic lamina to the 
subintimal ayer. Continued proliferation of these 
SMCs and their deposition of extracellular matrix 
lead to vessel wall thickening and luminal narrowing. 
The accumulation of monocytes and lympho- 
cytes is a prominent feature in human atherosclerosis 
and experimental intimal hyperplasia. 4-6 They are as- 
sumed to contribute to the initiation and progression 
ofintimal esion formation by secretion of a variety of 
inflammatory mediators, cytokines, and growth fac- 
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tors. s,7,8 Secretory products of monocytes and mac- 
rophages can serve as chemoattractants or mito- 
gens 9-1z for vascular SMCs and can therefore 
promote SMC accumulation within the intima. 
One of the mechanisms ofmonocyte infiltration 
into the intima is the monocyte-endothelial cell in- 
teractions, which are mediated by adhesion mole- 
cules expressed on the surface of monocytes and 
endothelium cells. One of the adhesion molecules on 
monocytes i  a [31-integrin molecule, very late anti- 
gen-4 (VLA-4; CD49d/CD29; c~4[Bx-integrin). 12 
VLA-4 participates in both cell-cell and cell-matrix 
interactions. VLA-4 interacts with endothelial ligand 
vascular cell adhesion molecule-1 (VCAM-1; 
CD106) la and with the matrix protein fibronectin. 1
Expression of VCAM-1 on unstimulated endothe- 
lium is very low. x~ However, expression of this mol- 
ecule is greatly increased by vessel injury or by stim- 
ulation of endothelium with interleukin-1 or tumor 
necrosis factor-&. 16 
SMCs do not express VCAM-1 protein or mes- 
senger ribonucleic acid in the normal aortic wall or in 
tissue culture during basal conditions. ~r,ls How- 
ever, VCAM-1 is expressed by phenotypically al- 
tered or modulated SMCs in rabbit intimal hyper- 
plastic lesions and in human coronary artery 
plaque, 19,2° suggesting an alternative pathway of 
monocyte infiltration into intima by direct SMC- 
monocyte interaction. 
Recently it has been reported that administration 
of anti-VLA-4 antibody significantly reduced (by 
approximately 70%) the stimulated influx of mono- 
cytes into the intima in a rabbit carotid artery injury 
model. 21 The marked benefit observed implies that 
this approach could have important therapeutic im- 
plications for limiting the response to arterial injury 
in clinical settings. 
In this report, the erects of anti-VLA-4 antibody 
on the development of intimal proliferative lesions 
after mechanical injury to normal arteries were stud- 
ied in a nonhuman primate model. Baboons were 
chosen as the experimental nimal because of their 
primate vascular anatomy and because the primate 
homeostatic mechanism 22,2s is similar to that in hu- 
mans. Experimental rterial injury was produced by 
surgical carotid artery endarterectomy, a method 
simulating therapeutic procedures performed in hu- 
mans. In each case, injury sites were evaluated after 4 
weeks by quantitative morphometric analysis, cell 
proliferation, and monocyte infiltration, with results 
in animals treated with anti'VLA-4 antibody com- 
pared with those obtained in untreated control ani- 
mals. 
MATERIAL AND METHODS 
Anti-VLA-4 antibody. Anti-VLA-4 monoclo- 
nal antibody was endotoxin-free, protein A-purified 
hmnanized anti-% (CD49d) monoclonal antibody 
(hHP1/2) that was a gift from Biogen Inc., Cam- 
bridge, Mass. A murine anti-VLA-4 antibody 
(HP1/2) was modified to contain 96% human 
sequence by grafting CD receptor-binding do- 
mains from both heavy and light chains onto hu- 
man frameworks and a human immunoglobulin 
G4 constant region. Human IgG was selected to 
eliminate antibody effector function, hHP1/2 was 
equipotent with murine HP1/2,  both in vitro and 
in vivo. 24-26 
Plasma levels of anti-VLA-4 monoclonal anti- 
body were determined with use of antibody-sand- 
wich enzyme-linked immunoabsorbent assays. The 
assay system used a polyclonal antibody raised in 
rabbits against recombinant human VLA-4 as the 
capture antibody. The same antibody conjugated to 
horseradish peroxidase was used as the signal anti- 
body. The sensitivity of the assay was 100 pg/ml. 
Animal model. Eight juvenile male baboons 
(Papio cynocephalus; age range, 2 to 3 years; weight 
range, 13 to 18 kg) were used in this study. Five 
animals were assigned to receive treatment and the 
other three animals erved as control subjects. Bilat- 
eral endarterectomies of carotid arteries were per- 
formed as previously described. 27-29 In brief, the 
common carotid artery was dissected at about 5 cm 
in length under general anesthesia and sterile condi- 
tions. The artery was clamped, divided, and everted. 
A 1 cm endarterectomy was performed on the 
everted artery by fine forceps. This procedure in- 
volved mechanical removal of the normal intima and 
a partial thiclmess of the media (about one half). 
After endarterectomy, thevessel was returned to its 
normal configuration, and anastomosis was per- 
formed. Treated animals received an intravenous bo- 
lus injection ofanti-VLA-4 antibody (3 mg/kg, Bio- 
gen Inc., Cambridge, Mass.) during surgery and 
again at 2 weeks. Control animals received saline 
injection. Animals were killed at 4 weeks by in vivo 
pressure-perfusion fixation. 28 Specimens were har- 
vested and fixed in 10% buffered formalin (Baxter 
Diagnostics Inc., McGraw Park, Ill.). M1 animal pro- 
cedures and care were performed in accordance with 
the Principles of Laboratory Animal Care and the 
Guidelines for the Care and Use of Laboratory Ani- 
mals (National Institues of Health publication No. 
80-23, revised 1985). 
Histology and morphometry. After fixation, 
arteries embedded inparaffin were sectioned at inter- 
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Table I. Macrophages at sites of carotid artery endarterectomy 
Reduction Student test 
Treated (n = 9) Control (n = 6) (%) (p value) * 
Intirna (cells/section) 15.78 + 3.05 33.50 _+ 6.13 53 <0.001 
Media (cells/section) 18.33 -- 3.56 19.50 _+ 2.63 6 0.511 
• A p value less than 0.05 is considered significant. 
vals of 1 to 2 mm through the endarterectomized 
segments and at 5 mm intervals along the entire 
specimens. Five-micrometer sections were cut and 
stained with hematoxylin and eosin and Verhoeff- 
Masson's tain. Morphometric measurements of the 
intimal thickness, intimal area, and medial area were 
performed with a computer-assisted display system 
(Thomas Optical, Columbus, Ga.) and image analy- 
sis software (Optimas, Bioscan, Inc., Edmonds, 
Wash.) as previously described. 28,3°,31 
Immunocytochemistry. The avidin-biotin com- 
plex immunoperoxidase procedure (LSAB Kit, Dako 
Co., Carpenteria, Calif.) was used to identify deter- 
minants that characterize proliferating cells and mac- 
rophages, as previously described. 32,33 In brief, 
VCAM-1 was identified with antihuman VCAM-1 
polyclonal antibody (R&D Systems, Minneapolis, 
Minn.). Proliferating cells were identified with anti- 
proliferating cell nuclear antigen (PCNA; Dako 
Co.). Macrophages were identified with antihuman 
macrophage monoclonal antibody (HAM56; Dako 
Co.). Positively stained cells were quantified manu- 
ally with use of a cell-counting technique under a 
microscope (×400). All positively stained cells in the 
intima and the media on each slide at the endarterec- 
tomized sites were counted separately. For the cell 
proliferation rate, the number of PCNA positively 
stained cells was expressed as a percentage of total 
cells to arrive at the PCNA index. A minimum of 10 
fields were quantified per section. Macrophages were 
expressed as the number of HAM56 positively 
stained cells per tissue section. Comparisons between 
groups were made with use of a Student test (two- 
tailed). Values are given as mean values _+ SE. Results 
were considered significant if the p value was less 
than 0.05. 
RESULTS 
All of the animals urvived the experimental pro- 
cedures with no clinical side effects. At tissue harvest- 
ing, all carotid arteries were patent, except for one 
that was occluded in a baboon in the group treated 
with the anti-VLA-4 antibody. The lumen of the 
occluded artery was filled with organized thrombus, 
and no fresh thrombus was observed. No clear inti- 
mal layer was observed at endarterectomized site, 
indicating that thrombosis probably occurred at an 
early stage after endarterectomy. Nine arteries in the 
treated group were compared with six arteries in the 
control group with respect o the number of macro- 
phages, cell proliferation, and morphometric mea- 
surements. All patent arteries howed intimal hyper- 
plasia and endothelium-like c ll coverage on luminal 
surfaces at endarterectomized sites. Immunostaining 
indicated that VCAM- 1 was expressed on endotheli- 
um-like cells and SMCs at the endarterectomized 
segments of carotid arteries. There were no notable 
differences for VCAM- 1 staining between the treated 
and control arteries. 
Circulating levels of  anti-VLA-4 antibody. 
During the study, antigenic oncentrations of circu- 
lating anti-VLA-4 monoclonal antibody were mea- 
sured each week. The initial serum levels averaged 
3.5 + 2.1 txg/ml and declined over the subsequent 2 
weeks before the second administration, but the lev- 
els always exceeded the concentration that saturated 
monocyte VLA-4-receptors, that is, 0.1 Ixg/ml. On 
the basis of these data, the Ts0 disappearance time 
was estimated to be approximately 10 days. 
Macrophages. The results of quantitative distri- 
bution of macrophages at the endarterectomized 
sites of carotid arteries arc given in Table I. Stained 
sections are shown in Fig. 1. The number of macro- 
phages in the intimal tissues was significantly reduced 
in the treated arteries compared with that in the 
control vessels (15.78 2 3.05 cells/section versus 
33.50 _+ 6.13 cells/section; p < 0.001). However, 
the number of macrophages in the remaining media 
did not showed a significant difference (p > 0.5). In 
the control vessels, more macrophages were present 
in the intima than in the remaining media. Thus, 
anti-VLA-4 antibody treatment significantly reduced 
the number ofmacrophages in intimal tissues but did 
not affect the distribution of macrophages in the 
remaining media at the endarterectomized sites of 
carotid arteries. 
Cell proliferation. Intimal cell proliferation at 
endarterectomized sites of carotid arteries was as- 
sessed by immunostaining for PCNA (Table II). The 
PCNA staining index was significantly lower (p < 
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Fig. 1. Histologic cross-sections at sites of carotid artery endarterectomy. Greater intimal 
hyperplasia developed in the control arteries (A) than in the arteries treated with anti-VLA-4 
monoclonal antibody (B). L, Lumen; /, intima; M, media; A, adventitia. Blue represents 
collagen staining; black represents elastin staining; pink represents all other components. 
(Verhoeff-Masson's stain; original magnification X 100.) 
Table II. Cell proliferation at sites of carotid artery endarterectomy 
Reduction Student test 
Treated & = 9) Control (n = 6) (%) (p value) * 
Infima (PCNA%) 2.88 _+ 1.07 4.89 -+ 0.77 41 0.002 
Media (PCNA%) 1.19 _+ 0.86 1.44 + 0.41 17 0.505 
PCNA, Proliferating cell nuclear antigen. 
*A p value less than 0.05 is considered significant. 
0.001) in the treated vessels (2.88% ___ 1.07%) com- 
pared with the control vessels (4.89% --- 0.77%). 
However, the difference in the PCNA staining index 
in the remaining media at endarterectomized sites 
was not significant between the treated and control 
groups (1.19% + 0.86% versus 1.44% _+ 0.41%, re- 
spectively; p > 0.5). Thus the anti-VLA-4 antibody 
treatment significantly reduced intimal cell prolifera- 
tion, without effect on medial cell proliferation at the 
endarterectomized sites of carotid arteries. 
Infimal hyperplasia. The findings ofintimal hy- 
perplasia of endarterectomized carotid arteries for 
the treated and control groups are given in Table III. 
Intimal area and thickness at the endarterectomized 
sites were significantly less in thc anti-VLA-4 anti- 
body treated group than in the control group (p < 
0.05). However, in the remaining medial areas there 
was no significant difference between the two groups 
(p > 0.3). Stained sections are shown in Fig. 1. Thus, 
systemic treatment of the anti-VLA-4 antibody sig- 
nificantly reduced the intimal hyperplasia, with no 
effect on the remaining media at the endarterecto- 
mized sites of carotid arteries. 
DISCUSSION 
Treatment of the baboons with an anti-VLA-4 
monoclonal antibody significantly inhibited mono- 
cyte infiltration into the intima at endarterectomized 
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Table III. Morphometric measurements a  ites of carotid artery endarterectomy 
Reduction Student test 
Treated (n = 9) Control (n = 6) (%) (p value) * 
Intimal thiclmess (mm) 0.16 _+ 0.07 0.27 + 0.03 40 0.003 
Intimal area (mm 2) 1.10 _+ 0.68 2.00 _+ 0.52 45 0.019 
Medial area (mm 2) 1.19 +- 0.40 1.39 -4- 0.39 NA 0.385 
• A p value less than 0.05 is considered significant. 
sites of carotid arteries by approximately 53% com- 
pared with the control baboons. This result is consis- 
tent with previous findings in a rabbit model 21 and in 
a tissue culture study3 s 
Recently, monocyte migration has been recog- 
nized as having an important endothelial cell-depen- 
dent component. This mechanism involves the acti- 
vation of endothelial cells by cytokines uch as 
interleuldn-1 and tumor necrosis factor-~ and by the 
bacterial product endotoxin lipopolysaccharides. 12 
In this condition, endothelial cells undergo pro- 
found functional alterations and express adhesion 
molecules for monocytes. This process involves in- 
creased surface xpression on the endothelial cells of 
the membrane glycoproteins E-selectin, intercellu- 
lar adhesion molecule-1 (ICAM-1), and VCAIVI- 
1.12,16,34 These molecules on the endothelium inter- 
act with the CDl l /CD18 and the VLA-4, respec- 
tively, on leukocytes, including monocytes. 12,1a,33 
Therefore monocyte infiltration consists of CD l l /  
CD18-dependent and VLA-4-dependent path- 
ways. 21,3a In this report, monocyte infiltration was 
partially inhibited because only the VLA-4 pathway 
was blocked. Kling et al. 2~ reported previously that 
the complete abolishment of monocyte influx was 
achieved by anti-VLA-4 plus ant i -CDl l /CD18 in 
rabbit carotid arteries. SMCs do not express ICAM-1 
and VCAM-1 in normal arteries.17 However, pheno- 
typically altered or modulated SMCs do express both 
ICAM-1 and VCAM-1 in injured rabbit arteries and 
in human coronary artery plaque, 19,2° suggesting 
that both CDl l /CD18-  and VLA-4-dependent 
pathways ofmonocyte infiltration could be present at 
endarterectomized sites of arteries. 
In this study, cell proliferation rates and intimal 
thickening at endarterectomized sites were signifi- 
cantly decreased in carotid arteries treated with anti- 
VLA-4 monoclonal antibody compared with un- 
treated control vessels. These results correlated with 
monocyte distribution i the intimal tissues. It is less 
likely that the anti-VLA-4 antibody may exert a di- 
rect suppressive effect on SMC migration and prolif- 
eration because VLA-4 has not to date been detected 
on adult vascular SMCs, 17,36 although c~4 expression 
has been detected on fetal SMCs. 37 Thus the number 
of monocytes and macrophages could be the sole 
cause of differing cell proliferation rates and intimal 
thickening between the treated and control groups. 
Macrophages derive primarily from circulating 
monocytes but possibly also, to some degree, from 
resident macrophages found within the surrounding 
tissues. Circulating monocytes differentiate into in- 
flammatory monocytes, macrophages and, finally, ac- 
tivated macrophages. Activated macrophages have 
been shown by numerous in vivo and in vitro studies 
to release products the affect .endothelial cell, SMC, 
and fibroblast proliferation. These products include 
platelet-derived growth factor, interleuldn-1, basic 
fibroblast growth factor, transforming growth fac- 
tor-J3, and tumor necrosis factor-oc a84° This was first 
reported by Leibovich and Ross in 1975.38 Release of 
these macrophage-derived growth factors was consis- 
tently shown to be dependent on activation of the 
macrophages. 39,4° 
A role of monocyte infiltration in intimal esion 
formation has been shown in several animal models. 
For example, after balloon injury in diet-induced 
atherosclerotic rabbit iliac arteries, immunochemical 
staining showed early monocyte infiltration that pre- 
ceded intimal SMC accumulation. With progressive 
lesion formation, macrophages predominated deeper 
in the intima near the internal elastic lamina, whereas 
SMCs predominated nearer to the lumen. 41 These 
macrophage distribution and intimal cell prolifera- 
tion patterns are very similar to those found in the 
model in this report. Intimal thickening elicited by 
balloon catheter injury in rat carotid arteries was 
reduced after inhibition of the accumulation of 
monocytes inthe intima, 6suggesting a role ofmono- 
cytes in mediating intimal SMC accumulation. This 
result is also consistent with our data in the baboon 
model. Thus, blocldng monocyte infiltration into the 
intima has a significant potential benefit in inhibiting 
intimal esion formation. 
In summary, the baboon model ofintimal hyper- 
plasia in endarterectomized a~ceries has been used in 
this study to investigate he therapeutic effects of an 
anti-VLA-4 monoclonal antibody. The data from 
JOURNAL OF VASCULAR SURGERY 
92 Lumsden et al. luly 1997 
this study show that b lock ing monocyte  adhes ion by 
ant i -VLA-4  ant ibodies signif icantly reduces the 
number  o f in t ima l  macrophages ,  int imal  cell prol ifer- 
at ion,  and int imal  hyperplasia at the endarterecto-  
mized  sites o f  carot id arteries. This  study supports a 
central  role for macrophages  in the deve lopment  o f  
int imal hyperplasia nd may suggest  a new therapeu-  
tic strategy to prevent  clinical restenosis. 
We thank Ms. Connie Miko and Ms. Carolyn Suwyn 
for their expert echnical assistance in tissue processing and 
histology procedures, and Ms. Deborah White for her 
laboratory assistance. 
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